• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024

    8/6/24 4:01:38 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DERM alert in real time by email

    SCOTTSDALE, Ariz., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its second quarter 2024 financial results after the U.S. financial markets close on Monday, August 12, 2024. Journey Medical management will conduct a conference call and audio webcast on Monday, August 12, 2024 at 4:30 p.m. ET.

    To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the Journey Medical conference call. Participants can register for the conference by navigating to https://dpregister.com/sreg/10190841/fd0fed9bae. Please note that registered participants will receive their dial-in number upon registration.

    A live audio webcast can be accessed on the News and Events page of the Investors section of Journey Medical's website, www.journeymedicalcorp.com, and will remain available for replay for approximately 30 days after the conference call.

    About Journey Medical Corporation

    Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical") is a commercial-stage pharmaceutical company that primarily focuses on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The company currently markets seven branded and two generic products that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology's most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (NASDAQ:FBIO). Journey Medical's common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission ("SEC"). For additional information about Journey Medical, visit www.journeymedicalcorp.com.

    Company Contact:

    Jaclyn Jaffe

    Journey Medical Corporation

    (781) 652-4500

    [email protected]

    Media Relations Contact:

    Tony Plohoros

    6 Degrees

    (908) 591-2839

    [email protected]



    Primary Logo

    Get the next $DERM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $DERM
    $FBIO

    CompanyDatePrice TargetRatingAnalyst
    Journey Medical Corporation
    $DERM
    8/22/2024$9.00Buy
    Rodman & Renshaw
    Journey Medical Corporation
    $DERM
    6/28/2024$11.00Buy
    ROTH MKM
    Fortress Biotech Inc.
    $FBIO
    3/15/2024$10.00Buy
    ROTH MKM
    Fortress Biotech Inc.
    $FBIO
    8/4/2022$6.00Buy
    Ladenburg Thalmann
    Journey Medical Corporation
    $DERM
    2/25/2022$9.00Overweight
    Cantor Fitzgerald
    Journey Medical Corporation
    $DERM
    12/16/2021$15.00Buy
    Roth Capital
    Journey Medical Corporation
    $DERM
    12/7/2021$14.00Buy
    B. Riley Securities
    More analyst ratings

    $DERM
    $FBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™

      Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025 Expanding payer coverage supports the adoption of Emrosi as prescription demand continues to increase SCOTTSDALE, Ariz., July 14, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that 65% of the 187 million commercial lives in the United States now have pharmacy benefit coverage for Emrosi™ (40 mg Minocycline Hydrochloride Modifi

      7/14/25 8:30:07 AM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma

      In an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, respectively Preclinical data support a novel combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus) to optimize clinical results FDA previously granted Orphan Drug Designation to Mustang for MB-108 for the treatment of malignant glioma WORCESTER, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical b

      7/7/25 8:30:55 AM ET
      $FBIO
      $MBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical to Join Russell 2000® and Russell 3000® Indexes

      SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as a result of their 2025 annual Russell Index reconstitution. "We are very pleased to be included in the Russell 2000® and Russell 3000

      6/24/25 8:30:29 AM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DERM
    $FBIO
    SEC Filings

    See more
    • Fortress Biotech Inc. filed SEC Form 8-K: Other Events

      8-K - Fortress Biotech, Inc. (0001429260) (Filer)

      7/16/25 5:25:41 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Journey Medical Corp (0001867066) (Filer)

      7/14/25 4:50:28 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Journey Medical Corp (0001867066) (Filer)

      6/26/25 4:05:53 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DERM
    $FBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT, CEO & CHAIRMAN Rosenwald Lindsay A Md bought $1,404,581 worth of shares (763,359 units at $1.84), increasing direct ownership by 26% to 3,657,264 units (SEC Form 4)

      4 - Fortress Biotech, Inc. (0001429260) (Issuer)

      9/25/24 4:45:04 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President, CEO & Chairman Rosenwald Lindsay A Md bought $37,418 worth of SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK (5,000 units at $7.48), increasing direct ownership by 4% to 127,500 units (SEC Form 4)

      4 - Fortress Biotech, Inc. (0001429260) (Issuer)

      7/15/24 4:05:14 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Jin David bought $3,750 worth of SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK (500 units at $7.50) (SEC Form 4)

      4 - Fortress Biotech, Inc. (0001429260) (Issuer)

      7/12/24 8:42:21 AM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DERM
    $FBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Journey Medical Corporation

      SC 13G - Journey Medical Corp (0001867066) (Subject)

      11/29/24 2:00:25 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Fortress Biotech Inc.

      SC 13G - Fortress Biotech, Inc. (0001429260) (Subject)

      10/25/24 10:15:19 AM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Fortress Biotech Inc.

      SC 13D/A - Fortress Biotech, Inc. (0001429260) (Subject)

      9/25/24 4:45:18 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DERM
    $FBIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Journey Medical to Join Russell 2000® and Russell 3000® Indexes

      SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as a result of their 2025 annual Russell Index reconstitution. "We are very pleased to be included in the Russell 2000® and Russell 3000

      6/24/25 8:30:29 AM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

      SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, is pleased to announce the promotion of Ramsey Alloush, currently General Counsel, to the position of Chief Operating Officer ("COO"). Mr. Alloush will continue to also serve as the Company's General Counsel. Claude Maraoui, President and Chief Executive Officer of Journey Medical, commented, "Ramsey's promotion to COO reflects

      4/1/25 4:01:16 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors

      SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that on July 9, 2024, it appointed Michael C. Pearce to its Board of Directors. Mr. Pearce is a principal investor with an emphasis on healthcare. Since 2015, he has served as an advisor to EP Group and board member of its predecessor parent company, Evening Post Industries ("EPI"). At EPI, he served on the audit, compensation, and inves

      7/11/24 4:05:39 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DERM
    $FBIO
    Financials

    Live finance-specific insights

    See more
    • Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

      Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late March 2025 Phase 3 Clinical Trial Results for Emrosi Published in JAMA Dermatology Emrosi Now Included in Updated National Rosacea Society Treatment Algorithms Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz., May 14, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Admin

      5/14/25 4:01:35 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates

      UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Special meeting of stockholders to vote on Merger to take place on May 28, 2025 WALTHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced financial results for the first quarter ended March 31, 2025, and recent corporate updates. Recent Corporate Updates: In December 2024, Checkpoint announced that the U.S. Food and Drug Administration ("FDA") approved UNLOXCYT™ (cosibelimab-ipdl) for the tr

      5/13/25 4:15:51 PM ET
      $CKPT
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

      SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2025 financial results after the U.S. financial markets close on Wednesday, May 14, 2025. Journey Medical management will conduct a conference call and audio webcast on Wednesday, May 14, 2025 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. s

      5/7/25 4:01:25 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DERM
    $FBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Journey Medical with a new price target

      Rodman & Renshaw initiated coverage of Journey Medical with a rating of Buy and set a new price target of $9.00

      8/22/24 7:21:37 AM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ROTH MKM resumed coverage on Journey Medical with a new price target

      ROTH MKM resumed coverage of Journey Medical with a rating of Buy and set a new price target of $11.00

      6/28/24 7:38:15 AM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ROTH MKM resumed coverage on Fortress Biotech with a new price target

      ROTH MKM resumed coverage of Fortress Biotech with a rating of Buy and set a new price target of $10.00

      3/15/24 7:18:10 AM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DERM
    $FBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Toledano Miranda Jayne was granted 7,173 shares, increasing direct ownership by 9% to 88,618 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      7/7/25 9:50:54 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Rosenwald Lindsay A Md was granted 7,173 shares, increasing direct ownership by 5% to 161,146 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      7/7/25 9:50:05 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Pearce Michael Cooper was granted 7,173 shares, increasing direct ownership by 24% to 37,173 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      7/7/25 9:48:55 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care